| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/0092-8674(95)90013-6 |
| P698 | PubMed publication ID | 7540117 |
| P2093 | author name string | M J Lenardo | |
| W Strober | |||
| S E Straus | |||
| J M Puck | |||
| A Y Lin | |||
| J K Dale | |||
| G H Fisher | |||
| F J Rosenberg | |||
| L A Middleton | |||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | autoimmune lymphoproliferative syndrome | Q1151300 |
| apoptotic process | Q14599311 | ||
| P304 | page(s) | 935-46 | |
| P577 | publication date | 1995-06-16 | |
| P1433 | published in | Cell | Q655814 |
| P1476 | title | Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome | |
| P478 | volume | 81 |
| Q48283620 | A FAS-ligand variant associated with autoimmune lymphoproliferative syndrome in cats |
| Q56876472 | A Novel Approach to Antigen-Specific Deletion of CTL with Minimal Cellular Activation Using α3 Domain Mutants of MHC Class I/Peptide Complex |
| Q34388164 | A common and recurrent 13-bp deletion in the autoimmune regulator gene in British kindreds with autoimmune polyendocrinopathy type 1 |
| Q24301360 | A congenital mutation of the novel gene LRRC8 causes agammaglobulinemia in humans |
| Q34564711 | A genetic disorder of lymphocyte apoptosis involving the fas pathway: the autoimmune lymphoproliferative syndrome |
| Q104486619 | A human case of GIMAP6 deficiency: a novel primary immune deficiency |
| Q42656563 | A missense mutation in the extracellular domain of Fas: the most common change in Argentinean patients with autoimmune lymphoproliferative syndrome represents a founder effect |
| Q38357354 | A mouse Fas-associated protein with homology to the human Mort1/FADD protein is essential for Fas-induced apoptosis |
| Q41609169 | A mutation in caspase-9 decreases the expression of BAFFR and ICOS in patients with immunodeficiency and lymphoproliferation |
| Q57078484 | A new peak in the ALPS |
| Q41230653 | A novel function of RIP1 in postnatal development and immune homeostasis by protecting against RIP3-dependent necroptosis and FADD-mediated apoptosis |
| Q58554162 | A novel mutation with variable expressivity in a family with unicentric and idiopathic multicentric Castleman disease |
| Q73023757 | A pivotal role of cell-bound but not soluble CD4 molecules in full development of lupus-like manifestations in MRL-Fas(lprcg)/Fas(lprcg) mice |
| Q33816818 | A portrait of the Bcl-2 protein family: life, death, and the whole picture |
| Q36595156 | A rapid ex vivo clinical diagnostic assay for fas receptor-induced T lymphocyte apoptosis |
| Q36367334 | A tumor-suppressor function for Fas (CD95) revealed in T cell-deficient mice |
| Q47358927 | A variant of death-receptor 3 associated with rheumatoid arthritis interferes with apoptosis-induction of T cell |
| Q33807422 | ALPS-ten lessons from an international workshop on a genetic disease of apoptosis |
| Q34069952 | APO-1/Fas gene: Structural and functional characteristics in systemic lupus erythematosus and other autoimmune diseases |
| Q35849941 | Abnormal disulfide-linked oligomerization results in ER retention and altered signaling by TNFR1 mutants in TNFR1-associated periodic fever syndrome (TRAPS) |
| Q58204990 | Abnormal expression and function of Fas ligand of lacrimal glands and peripheral blood in Sjögren's syndrome patients with enlarged exocrine glands |
| Q73886872 | Activation of T-cells through an antigen-independent alternative pathway induces precocious sensitivity to Fas-induced apoptosis |
| Q33864763 | Activation of apoptosis pathways by anticancer treatment. |
| Q73481223 | Activation of protein kinase C attenuates early signals in Fas-mediated apoptosis |
| Q39444883 | Activation-dependent transcriptional regulation of the human Fas promoter requires NF-kappaB p50-p65 recruitment |
| Q24623371 | Advances in the management and understanding of autoimmune lymphoproliferative syndrome (ALPS) |
| Q40912684 | Aging and regulation of apoptosis |
| Q35787084 | Alterations of Fas (Apo-1/CD95) gene in cutaneous malignant melanoma |
| Q54000134 | An alternatively spliced long form of Fas apoptosis inhibitory molecule (FAIM) with tissue-specific expression in the brain. |
| Q24313206 | An autoimmune disease, APECED, caused by mutations in a novel gene featuring two PHD-type zinc-finger domains |
| Q35973425 | An innately interesting decade of research in immunology |
| Q90383784 | An updated review on phenocopies of primary immunodeficiency diseases |
| Q37266079 | Analysis of single nucleotide polymorphisms in the FAS and CTLA-4 genes of peripheral T-cell lymphomas |
| Q28347243 | Anti-CD3-induced and anti-Fas-induced apoptosis in systemic lupus erythematosus (SLE) |
| Q33341289 | Anti-platelet antibodies associated with the Canale-Smith syndrome bind to the same platelet glycoprotein complexes as those of idiopathic thrombocytopenic purpura patients |
| Q73190447 | Apoptosis |
| Q77746573 | Apoptosis and antiphospholipid antibodies |
| Q34108820 | Apoptosis and autoimmunity: complement deficiency and systemic lupus erythematosus revisited |
| Q34214558 | Apoptosis and its clinical impact |
| Q41049050 | Apoptosis and the maintenance of homoeostasis in the immune system |
| Q35129735 | Apoptosis and transplantation tolerance. |
| Q28304002 | Apoptosis by death factor |
| Q34096282 | Apoptosis genes and autoimmunity. |
| Q73347827 | Apoptosis in a Fas-resistant, T-cell receptor-sensitive human leukaemic T-cell clone |
| Q34490943 | Apoptosis in cardiac transplant rejection |
| Q39568120 | Apoptosis in haematological malignancies |
| Q35091131 | Apoptosis in hematological disorders. |
| Q34074029 | Apoptosis in rheumatic diseases |
| Q35116684 | Apoptosis in the development and maintenance of the immune system |
| Q33541433 | Apoptosis of activated peripheral T cells |
| Q34395580 | Apoptosis regulators and their role in tumorigenesis |
| Q36852224 | Apoptosis signaling pathways and lymphocyte homeostasis |
| Q34404597 | Apoptosis, Part II: The role of mutated Fas genes in tumorigenesis. |
| Q34589870 | Apoptosis: molecular regulation of cell death and hematologic malignancies |
| Q36454468 | Apoptotic death of CD8+ T lymphocytes after immunization: induction of a suppressive population of Mac-1+/Gr-1+ cells |
| Q33782516 | Application of a Fas ligand encoding a recombinant adenovirus vector for prolongation of transgene expression |
| Q55297581 | Autoimmune Lymphoproliferative Syndrome-FAS Patients Have an Abnormal Regulatory T Cell (Treg) Phenotype but Display Normal Natural Treg-Suppressive Function on T Cell Proliferation. |
| Q37298573 | Autoimmune lymphoproliferative syndrome caused by a homozygous null FAS ligand (FASLG) mutation |
| Q39413664 | Autoimmune lymphoproliferative syndrome due to FAS mutations outside the signal-transducing death domain: molecular mechanisms and clinical penetrance |
| Q80547251 | Autoimmune lymphoproliferative syndrome in a patient with common variable immunodeficiency: dichotomy of apoptosis |
| Q40323202 | Autoimmune lymphoproliferative syndrome mimicking chronic active Epstein-Barr virus infection. |
| Q73368264 | Autoimmune lymphoproliferative syndrome presenting with glomerulonephritis |
| Q34389314 | Autoimmune lymphoproliferative syndrome with defective Fas: genotype influences penetrance |
| Q40408652 | Autoimmune lymphoproliferative syndrome-like syndrome presented as lupus-like syndrome with mycobacterial joint infection evolved into the lymphoma |
| Q34114550 | Autoimmune lymphoproliferative syndrome. A human disorder of abnormal lymphocyte survival |
| Q26825740 | Autoimmune lymphoproliferative syndrome: an update and review of the literature |
| Q35074313 | Autoimmune lymphoproliferative syndrome: etiology, diagnosis, and management |
| Q48248134 | Autoimmune lymphoproliferative syndrome: molecular diagnosis in two families |
| Q47151016 | Autoimmune lymphoproliferative syndrome: more than a FAScinating disease. |
| Q42810256 | Autoimmune lymphoproliferative syndrome: response to mycophenolate mofetil and pyrimethamine/sulfadoxine in a 5-year-old child |
| Q35091428 | Autoimmune lymphoproliferative syndromes: genetic defects of apoptosis pathways |
| Q49644376 | Autoimmunity and primary immunodeficiency: two sides of the same coin? |
| Q33885931 | Autoimmunity as a consequence of retrovirus-mediated expression of C-FLIP in lymphocytes |
| Q36618394 | Autoimmunity versus tolerance: can dying cells tip the balance? |
| Q40953607 | Autoimmunity. The Fas track. |
| Q36632364 | Autoimmunity: twenty years in the Fas lane |
| Q42741742 | Autoreactive MZ and B-1 B-cell activation by Faslpr is coincident with an increased frequency of apoptotic lymphocytes and a defect in macrophage clearance |
| Q55671193 | Autosomal dominant anhidrotic ectodermal dysplasias at the EDARADD locus |
| Q36974300 | B cells in glomerulonephritis: focus on lupus nephritis. |
| Q41312443 | B cells in systemic autoimmune disease: recent insights from Fas-deficient mice and men. |
| Q37689611 | Balancing immunity and tolerance: deleting and tuning lymphocyte repertoires |
| Q64018952 | Bcl–2 protects from lethal hepatic apoptosis induced by an ant–Fas antibody in mice |
| Q89029472 | Beyond Cell Death: New Functions for TNF Family Cytokines in Autoimmunity and Tumor Immunotherapy |
| Q38748557 | Beyond TNF: TNF superfamily cytokines as targets for the treatment of rheumatic diseases |
| Q34357751 | Binding of FADD and caspase-8 to molluscum contagiosum virus MC159 v-FLIP is not sufficient for its antiapoptotic function |
| Q47992184 | Biochemical mechanisms of IL-2-regulated Fas-mediated T cell apoptosis |
| Q35145645 | Biology of FasL. |
| Q45113910 | Biology of the interleukin-2 receptor |
| Q58449593 | Biophysical and cell-based evidence for differential interactions between the death domains of CD95/Fas and FADD |
| Q37618832 | Bone marrow findings in autoimmune lymphoproliferative syndrome with germline FAS mutation |
| Q36370844 | CD28-dependent activation of protein kinase B/Akt blocks Fas-mediated apoptosis by preventing death-inducing signaling complex assembly. |
| Q36229478 | CD40 ligand and MHC class II expression are essential for human peripheral B cell tolerance |
| Q73990329 | CD8+ T cells in large granular lymphocyte leukemia are not defective in activation- and replication-related apoptosis |
| Q53939721 | CD95 (APO-1/FAS) deficiency in infant acute lymphoblastic leukemia: detection of novel soluble Fas splice variants. |
| Q57623671 | CD95 expression and CD95-mediated apoptosis of T cells in multiple sclerosis. No differences from normal individuals and no relation to HLA-DR2. |
| Q28142072 | CD95's deadly mission in the immune system |
| Q57384650 | CD95(APO-1/Fas)-mediated apoptosis in normal and malignant liver, colon, and hematopoietic cells |
| Q77903149 | CD95(APO-1/Fas)-mediated apoptosis: live and let die |
| Q42403505 | CD95-Mediated Calcium Signaling Promotes T Helper 17 Trafficking to Inflamed Organs in Lupus-Prone Mice |
| Q37951369 | CD95-mediated cell signaling in cancer: mutations and post-translational modulations |
| Q56906450 | CTLA4IgG gene delivery prevents autoantibody production and lupus nephritis in MRL/lpr mice |
| Q24299040 | Calmodulin binding to the Fas death domain. Regulation by Fas activation |
| Q36403055 | Caspase-8 deficiency in T cells leads to a lethal lymphoinfiltrative immune disorder |
| Q53867825 | Caspase-8L expression protects CD34+ hematopoietic progenitor cells and leukemic cells from CD95-mediated apoptosis. |
| Q35129694 | Caspases and T lymphocytes: a flip of the coin? |
| Q36430147 | Caspases at the crossroads of immune-cell life and death |
| Q34082790 | Cell death control in lymphocytes. |
| Q38926368 | Cell death in the pathogenesis of systemic lupus erythematosus and lupus nephritis |
| Q35145789 | Cell-death signaling and human disease |
| Q52182217 | Cellular and molecular basis of immunodeficiencies: their consequences for the development and induction of the immune response. |
| Q33558240 | Characterization of calmodulin-Fas death domain interaction: an integrated experimental and computational study |
| Q41737519 | Clinical effects of mutations to CD95 (Fas): relevance to autoimmunity? |
| Q33496872 | Clinical, immunological, and pathological consequences of Fas-deficient conditions |
| Q33840464 | Cloak and dagger in the avoidance of immune surveillance |
| Q28206261 | Cloning and characterization of the highly expressed ETEA gene from blood cells of atopic dermatitis patients |
| Q34440616 | Clues to immune tolerance: the monogenic autoimmune syndromes |
| Q73968545 | Clustering of distinct autoimmune diseases associated with functional abnormalities of T cell survival in children |
| Q30838565 | Co-inherited mutations of Fas and caspase-10 in development of the autoimmune lymphoproliferative syndrome |
| Q41872230 | Conditional Fas-associated death domain protein (FADD): GFP knockout mice reveal FADD is dispensable in thymic development but essential in peripheral T cell homeostasis |
| Q37008175 | Conformation and free energy analyses of the complex of calcium-bound calmodulin and the Fas death domain |
| Q35788898 | Constitutive expression of c-FLIP in Hodgkin and Reed-Sternberg cells |
| Q33500292 | Correction of Fas (CD95) deficiency by haploidentical bone marrow transplantation. |
| Q33774541 | Cyclosporin A-sensitive transcription factor Egr-3 regulates Fas ligand expression |
| Q73622347 | Cysteine protease CPP32, but not Ich1-L, is expressed in germinal center B cells and their neoplastic counterparts |
| Q57078478 | Cytomegalovirus infection in infants with autoimmune lymphoproliferative syndrome (ALPS) |
| Q48836752 | DNA adducts and chronic degenerative disease. Pathogenetic relevance and implications in preventive medicine. |
| Q35990527 | Death effector domain-containing herpesvirus and poxvirus proteins inhibit both Fas- and TNFR1-induced apoptosis |
| Q30443591 | Death pathways in T cell homeostasis and their role in autoimmune diabetes |
| Q24320210 | Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-kappaB pathway |
| Q35176421 | Death receptor signaling and autoimmunity |
| Q36290306 | Death receptors and caspases: role in lymphocyte proliferation, cell death, and autoimmunity |
| Q41428240 | Decreased activation-induced cell death by EBV-transformed B-cells from a patient with autoimmune lymphoproliferative syndrome caused by a novel FASLG mutation. |
| Q35132088 | Defective CD95/APO-1/Fas signal complex formation in the human autoimmune lymphoproliferative syndrome, type Ia. |
| Q28201537 | Defective T cell activation and autoimmune disorder in Stra13-deficient mice |
| Q77787538 | Defective apoptosis due to a point mutation in the death domain of CD95 associated with autoimmune lymphoproliferative syndrome, T-cell lymphoma, and Hodgkin's disease |
| Q77336828 | Defective clearance of nucleosomes and systemic lupus erythematosus |
| Q47675146 | Defective function of Fas in T cells from paediatric patients with autoimmune thyroid diseases. |
| Q53929277 | Deficient activation and resistance to activation-induced apoptosis of CD8+ T cells is associated with defective peripheral tolerance in nonobese diabetic mice. |
| Q36708937 | Deregulation of Fas ligand expression as a novel cause of autoimmune lymphoproliferative syndrome-like disease |
| Q73862693 | Detection of alternatively spliced variant messages of Fas gene and mutational screening of Fas and Fas ligand coding regions in peripheral blood mononuclear cells derived from silicosis patients |
| Q102059106 | Determining the effector response to cell death |
| Q33818169 | Development of disseminated histiocytic sarcoma in a patient with autoimmune lymphoproliferative syndrome and associated Rosai-Dorfman disease |
| Q36416249 | Dichotomy between naïve and memory CD4(+) T cell responses to Fas engagement |
| Q40984215 | Die and let live: eliminating dangerous lymphocytes |
| Q40403935 | Dietary n-3 PUFAs augment caspase 8 activation in Staphylococcal aureus enterotoxin B stimulated T-cells |
| Q56880742 | Differential TCR Signaling Regulates Apoptosis and Immunopathology during Antigen Responses In Vivo |
| Q36158748 | Differential ability of T cell subsets to undergo activation-induced cell death |
| Q33735056 | Differential cytokine withdrawal-induced death sensitivity of effector T cells derived from distinct human CD8+ memory subsets |
| Q41769681 | Differential expression of human Fas mRNA species upon peripheral blood mononuclear cell activation |
| Q40640025 | Differential recruitment of caspase 8 to cFlip confers sensitivity or resistance to Fas-mediated apoptosis in a subset of familial lymphoma patients |
| Q37056318 | Disorders of apoptosis: mechanisms for autoimmunity in primary immunodeficiency diseases. |
| Q34986210 | Dissecting Fas signaling with an altered-specificity death-domain mutant: requirement of FADD binding for apoptosis but not Jun N-terminal kinase activation |
| Q41140348 | Dissociation of Fas-mediated cytotoxicity and FasL expression in a cytotoxic CD4+ T-cell clone. Comparative analysis of Fas-mediated cytotoxicity between a T-hybridoma and a T-cell clone |
| Q35879009 | Distinct domains of M-T2, the myxoma virus tumor necrosis factor (TNF) receptor homolog, mediate extracellular TNF binding and intracellular apoptosis inhibition. |
| Q33289658 | Dominant inhibition of Fas ligand-mediated apoptosis due to a heterozygous mutation associated with autoimmune lymphoproliferative syndrome (ALPS) Type Ib |
| Q35186959 | Double negative (DN) αβ T cells: misperception and overdue recognition |
| Q39251222 | Dual Role of Fas/FasL-Mediated Signal in Peripheral Immune Tolerance. |
| Q24642248 | Dual functions for the endoplasmic reticulum calcium sensors STIM1 and STIM2 in T cell activation and tolerance |
| Q34658574 | Dysregulation of apoptosis genes in hematopoietic malignancies. |
| Q28250725 | Early-onset lymphoproliferation and autoimmunity caused by germline STAT3 gain-of-function mutations |
| Q35145617 | Ectodysplasin signaling in development |
| Q35234813 | Effect of regular circus physical exercises on lymphocytes in overweight children |
| Q33910884 | Elevated interleukin-10: a new cause of dyslipidemia leading to severe HDL deficiency |
| Q36955782 | Elimination of antigen-presenting cells and autoreactive T cells by Fas contributes to prevention of autoimmunity |
| Q37264217 | Endoplasmic reticulum-resident E3 ubiquitin ligase Hrd1 controls B-cell immunity through degradation of the death receptor CD95/Fas |
| Q37711034 | Enhanced and accelerated lymphoproliferation in Fas-null mice |
| Q35763713 | Enhanced lymphocyte longevity and absence of proliferation and lymphocyte apoptosis in Quilty effects of human heart allografts |
| Q44120546 | Epigenetic changes in tumor Fas levels determine immune escape and response to therapy |
| Q41655689 | Errors of homeostasis and deregulated apoptosis |
| Q36380686 | Essential lymphocyte function associated 1 (LFA-1): intercellular adhesion molecule interactions for T cell-mediated B cell apoptosis by Fas/APO-1/CD95. |
| Q39239706 | Estimating the prevalence of functional exonic splice regulatory information |
| Q58709046 | Evaluation of serum uric acid level in systemic lupus erythematosus patients with normal and high pulmonary arterial hypertension |
| Q42325007 | Evolution of disease activity and biomarkers on and off rapamycin in 28 patients with autoimmune lymphoproliferative syndrome |
| Q36365810 | Expansion of cytokine-producing CD4-CD8- T cells associated with abnormal Fas expression and hypereosinophilia. |
| Q46863693 | Expansion or elimination of B cells in vivo: dual roles for CD40- and Fas (CD95)-ligands modulated by the B cell antigen receptor. |
| Q53985468 | Expression of Apo-3 and Apo-3L in primitive neuroectodermal tumours of the central and peripheral nervous system. |
| Q52971040 | Expression of TRAIL receptors in human autoreactive and foreign antigen-specific T cells. |
| Q36269726 | Expression of apoptosis-related genes in human oocytes and embryos |
| Q33388396 | Extreme lymphoproliferative disease and fatal autoimmune thrombocytopenia in FasL and TRAIL double-deficient mice |
| Q28767089 | FAS (CD95) mutations are rare in gastric MALT lymphoma but occur more frequently in primary gastric diffuse large B-cell lymphoma |
| Q51647360 | FAS Haploinsufficiency Caused by Extracellular Missense Mutations Underlying Autoimmune Lymphoproliferative Syndrome. |
| Q28235519 | FAS haploinsufficiency is a common disease mechanism in the human autoimmune lymphoproliferative syndrome |
| Q35387068 | FAS mRNA editing in Human Systemic Lupus Erythematosus |
| Q37680225 | FAS system deregulation in T-cell lymphoblastic lymphoma |
| Q34230777 | Fas (CD95, Apo-1) ligand gene transfer |
| Q44598129 | Fas A670G polymorphism, apoptotic capacity in lymphocyte cultures, and risk of lung cancer |
| Q36564552 | Fas activation of the p38 mitogen-activated protein kinase signalling pathway requires ICE/CED-3 family proteases |
| Q36365902 | Fas and the art of lymphocyte maintenance |
| Q41197270 | Fas expression and apoptosis in human B cells |
| Q37305254 | Fas expression on antigen-specific T cells has costimulatory, helper, and down-regulatory functions in vivo for cytotoxic T cell responses but not for T cell-dependent B cell responses |
| Q40962746 | Fas gene mutation in the progression of adult T cell leukemia |
| Q30987706 | Fas gene mutations in prostatic intraepithelial neoplasia and concurrent carcinoma: analysis of laser capture microdissected specimens |
| Q46562775 | Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction |
| Q71031959 | Fas ligand in human serum |
| Q53418059 | Fas ligand is highly expressed in acute leukemia and during the transformation of chronic myeloid leukemia to blast crisis. |
| Q37227679 | Fas ligand is not only expressed in immune privileged human organs but is also coexpressed with Fas in various epithelial tissues |
| Q28115268 | Fas ligand mutation in a patient with systemic lupus erythematosus and lymphoproliferative disease |
| Q53944128 | Fas ligand-expressing tumors induce tumor-specific protective immunity in the inoculated hosts but vaccination with the apoptotic tumors suppresses antitumor immunity. |
| Q51785360 | Fas promoter region gene polymorphism is associated with an increased risk for myocardial infarction. |
| Q36314636 | Fas receptor expression in germinal-center B cells is essential for T and B lymphocyte homeostasis |
| Q36285131 | Fas-independent death of activated CD4(+) T lymphocytes induced by CTLA-4 crosslinking |
| Q71834535 | Fas-induced programmed cell death is mediated by a Ras-regulated O2- synthesis |
| Q24612227 | Fas-ligand: privilege and peril |
| Q71118225 | Fas-mediated apoptosis is modulated by intracellular glutathione in human T cells |
| Q36454475 | Fas-mediated suicide of tumor-reactive T cells following activation by specific tumor: selective rescue by caspase inhibition |
| Q37541681 | Fas/CD95 prevents autoimmunity independently of lipid raft localization and efficient apoptosis induction |
| Q35557461 | Fascination with bacteria-triggered cell death: the significance of Fas-mediated apoptosis during bacterial infection in vivo |
| Q35748214 | Frequent deletion of Fas gene sequences encoding death and transmembrane domains in nasal natural killer/T-cell lymphoma. |
| Q35561571 | Function and regulation of the CD95 (APO-1/Fas) ligand in the immune system |
| Q40913568 | Functional aspects of apoptosis in hematopoiesis and consequences of failure |
| Q34429062 | Gene defects in the soma: some get it and some don't! |
| Q31117786 | Gene mutations: analysis in proliferative prostatic diseases using laser capture microdissection |
| Q40323055 | Genetic alterations in caspase-10 may be causative or protective in autoimmune lymphoproliferative syndrome |
| Q71972615 | Genetic basis of systemic lupus erythematosus |
| Q37142878 | Genetic defects of apoptosis and primary immunodeficiency |
| Q36593309 | Genetics of SLE in mice |
| Q33893349 | Genetics of systemic lupus erythematosus. Clinical implications |
| Q28943339 | Genome-wide association study identifies multiple risk loci for chronic lymphocytic leukemia |
| Q28138470 | Genomic organization and mutation analyses of the DR5/TRAIL receptor 2 gene in colorectal carcinomas |
| Q57398166 | Genomic profiling of interpopulation diversity guides prioritization of candidate-genes for autoimmunity |
| Q40993323 | Genomics is rapidly advancing precision medicine for immunological disorders |
| Q54806502 | Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. |
| Q43124182 | Gray platelet syndrome can mimic autoimmune lymphoproliferative syndrome |
| Q36400607 | HIV-1 directly kills CD4+ T cells by a Fas-independent mechanism |
| Q36768058 | HSF-1 activates the ubiquitin proteasome system to promote non-apoptotic developmental cell death in C. elegans. |
| Q36219516 | Harnessing programmed cell death as a therapeutic strategy in rheumatic diseases |
| Q30273613 | Hepatocyte nuclear factor (HNF)-4alpha induces expression of endothelial Fas ligand (FasL) to prevent cancer cell transmigration: a novel defense mechanism of endothelium against cancer metastasis |
| Q35351584 | High Fas ligand expression on lymphocytes in lesions of ulcerative colitis |
| Q35213325 | Higher grade transformation of follicular lymphoma: phenotypic tumor progression associated with diverse genetic lesions |
| Q36353207 | Histone deacetylase inhibitors prevent activation-induced cell death and promote anti-tumor immunity |
| Q41217153 | Hodgkin's disease. Diagnostic procedures |
| Q24633207 | How I treat autoimmune lymphoproliferative syndrome |
| Q35618118 | Human primary immunodeficiency diseases: a perspective |
| Q35130847 | IL-10/Janus kinase/signal transducer and activator of transcription 3 signaling dysregulates Bim expression in autoimmune lymphoproliferative syndrome |
| Q90281729 | IL1R8 Deficiency Drives Autoimmunity-Associated Lymphoma Development |
| Q61863688 | Identification and characterisation of polymorphisms in the promoter region of the human Apo-1/Fas (CD95) gene |
| Q54565164 | Identification and characterization of DEDDL, a human-specific isoform of DEDD. |
| Q24318423 | Identification and characterization of a new member of the TNF family that induces apoptosis |
| Q42856573 | Identification of Fas-L-expressing apoptotic T lymphocytes in normal human peripheral blood : in vivo suicide |
| Q31087661 | Identification of autoantibodies associated with systemic lupus erythematosus |
| Q38598383 | Identifying genetic determinants of autoimmunity and immune dysregulation. |
| Q37106307 | Immune deficiency disorders with autoimmunity and abnormalities in immune regulation-monogenic autoimmune diseases |
| Q35195215 | Immune disorders caused by defects in the caspase cascade |
| Q34477452 | Immune disorders in Hashimoto's thyroiditis: what do we know so far? |
| Q33502917 | Immunodeficiency with elevated IgM, lymphoid hyperplasia, autoimmune anemia, and thrombocytopenia |
| Q73726672 | Immunohistochemical analysis of CD30-positive lymphoproliferative disorders for expression of CD95 and CD95L |
| Q41737512 | Immunopathology of apoptosis--introduction and overview. |
| Q34223137 | Immunophenotyping |
| Q24530757 | Impaired apoptosis, extended duration of immune responses, and a lupus-like autoimmune disease in IEX-1-transgenic mice |
| Q36399434 | Impaired clearance of apoptotic cells promotes synergy between atherogenesis and autoimmune disease |
| Q40735828 | Inactivating mutations of the caspase-10 gene in gastric cancer |
| Q48284203 | Inactivation of the Fas gene by Alu insertion: retrotransposition in an intron causing splicing variation and autoimmune lymphoproliferative syndrome. |
| Q52655081 | Indolylmaleimide Derivative IM-17 Shows Cardioprotective Effects in Ischemia-Reperfusion Injury. |
| Q46642536 | Inducible nonlymphoid expression of Fas ligand is responsible for superantigen-induced peripheral deletion of T cells |
| Q34146806 | Inducible resistance to Fas-mediated apoptosis in B cells |
| Q34166328 | Induction of apoptosis and activation of NF-kappaB by CD95 require different signalling thresholds |
| Q41293478 | Induction of apoptosis in mature T cells by tumour necrosis factor |
| Q22010404 | Inherited human Caspase 10 mutations underlie defective lymphocyte and dendritic cell apoptosis in autoimmune lymphoproliferative syndrome type II |
| Q90631958 | Inherited variants at 3q13.33 and 3p24.1 are associated with risk of diffuse large B-cell lymphoma and implicate immune pathways |
| Q35168016 | Inhibition of Fas ligand in NOD mice unmasks a protective role for IL-10 against insulitis development |
| Q77485563 | Inhibition of fas death signals by FLIPs |
| Q36375511 | Inhibition of interleukin 2 signaling and signal transducer and activator of transcription (STAT)5 activation during T cell receptor-mediated feedback inhibition of T cell expansion |
| Q36368247 | Insulin-secreting cells derived from stem cells: clinical perspectives, hypes and hopes |
| Q99708569 | Integration of innate immune signaling by caspase-8 cleavage of N4BP1 |
| Q36763234 | Interaction between glutathione and apoptosis in systemic lupus erythematosus |
| Q28587823 | Interleukin-2 receptor α chain regulates the size and content of the peripheral lymphoid compartment |
| Q30713693 | Intramolecular epitope spreading among anti-caspase-8 autoantibodies in patients with silicosis, systemic sclerosis and systemic lupus erythematosus, as well as in healthy individuals |
| Q35787910 | Involvement of soluble CD95 in Churg-Strauss syndrome |
| Q42700395 | Janus Kinase Inhibitor Tofacitinib Shows Potent Efficacy in a Mouse Model of Autoimmune Lymphoproliferative Syndrome (ALPS). |
| Q36142583 | Laboratory evaluation of primary immunodeficiencies |
| Q36368991 | Lack of coreceptor allows survival of chronically stimulated double-negative alpha/beta T cells: implications for autoimmunity |
| Q33838008 | Lessons from Genetic Studies of Primary Immunodeficiencies in a Highly Consanguineous Population |
| Q83179996 | Let-7/miR-98 regulate Fas and Fas-mediated apoptosis |
| Q41901585 | Live and let die at TEMRA. |
| Q35538226 | Live and let die: regulatory mechanisms in Fas-mediated apoptosis. |
| Q45855746 | Liver cystic echinococcosis and human host immune and autoimmune follow-up: A review |
| Q41195420 | Looking beneath the surface: the cell death pathway of Fas/APO-1 (CD95). |
| Q49240035 | Loss of Fas (CD95/APO-1) regulatory function is an important step in early MALT-type lymphoma development |
| Q35349474 | Loss of c-REL but not NF-κB2 prevents autoimmune disease driven by FasL mutation |
| Q41861924 | Low frequency of FAS mutations in Reed-Sternberg cells of Hodgkin's lymphoma |
| Q62056316 | Lymphadenopathy driven by TCR-V8V1 T-cell expansion in FAS-related autoimmune lymphoproliferative syndrome |
| Q40068662 | Lymphocytic profiling in thyroid cancer provides clues for failure of tumor immunity. |
| Q41300846 | M-T2: a poxvirus TNF receptor homologue with dual activities. |
| Q33672489 | Many checkpoints on the road to cell death: regulation of Fas-FasL interactions and Fas signaling in peripheral immune responses |
| Q34136960 | Marginal zone B-cell dysfunction in ALPS. |
| Q42382043 | Marked mitigation of transplant vascular sclerosis in FasLgld (CD95L) mutant recipients. The role of alloantibodies in the development of chronic rejection |
| Q35212674 | Measuring T cell-mediated cytotoxicity using fluorogenic caspase substrates |
| Q44443182 | Mechanisms for T-cell selective cytotoxicity of arabinosylguanine |
| Q56609201 | Mechanisms of apoptosis |
| Q35899439 | Mechanisms of human autoimmunity |
| Q71425875 | Mechanisms of peripheral T cell deletion: anergized T cells are Fas resistant but undergo proliferation-associated apoptosis |
| Q41049046 | Mechanisms underlying T-cell tolerance |
| Q42093656 | Membrane-bound Fas ligand only is essential for Fas-induced apoptosis |
| Q37314479 | Membrane-bound Fas ligand requires RIP1 for efficient activation of caspase-8 within the death-inducing signaling complex |
| Q36675182 | Meta-analysis of genome-wide association studies discovers multiple loci for chronic lymphocytic leukemia |
| Q28216909 | Mitochondrial hyperpolarization and ATP depletion in patients with systemic lupus erythematosus |
| Q41290133 | Molecular and clinical aspects of apoptosis |
| Q34647002 | Molecular aspects of primary immunodeficiencies: lessons from cytokine and other signaling pathways. |
| Q40885317 | Molecular cloning and characterization of cynomolgus monkey Fas. |
| Q42687371 | Molecular cloning of feline Fas antigen and Fas ligand cDNAs |
| Q35176380 | Molecular regulation of T lymphocyte homeostasis in the healthy and diseased immune system |
| Q34001034 | Molecular steps of cell suicide: an insight into immune senescence |
| Q36368090 | Monocyte-mediated tumoricidal activity via the tumor necrosis factor-related cytokine, TRAIL. |
| Q37384657 | Monogenic autoimmune diseases: insights into self-tolerance |
| Q47869356 | Mutational analysis of Fas ligand gene in human non-Hodgkin lymphoma |
| Q37396889 | Mutations in CRADD Result in Reduced Caspase-2-Mediated Neuronal Apoptosis and Cause Megalencephaly with a Rare Lissencephaly Variant |
| Q53667090 | Mutations in TNFRSF13B encoding TACI are associated with common variable immunodeficiency in humans. |
| Q22010459 | Mutations in the human homologue of mouse dl cause autosomal recessive and dominant hypohidrotic ectodermal dysplasia |
| Q45740282 | Myxoma virus expresses a TNF receptor homolog with two distinct functions |
| Q35829141 | NRAS mutation causes a human autoimmune lymphoproliferative syndrome. |
| Q37670054 | Natural history of autoimmune lymphoproliferative syndrome associated with FAS gene mutations |
| Q33863208 | Natural variation in immune responsiveness, with special reference to immunodeficiency and promoter polymorphism in class II MHC genes |
| Q92109255 | Navigating the Fas lane to improved cellular therapy for cancer |
| Q34239719 | New advances in the diagnosis and treatment of autoimmune lymphoproliferative syndrome |
| Q36126352 | New take on comparative immunology: relevance to immunotherapy |
| Q34941147 | Nitric oxide as an inflammatory mediator in autoimmune MRL-lpr/lpr mice |
| Q34242689 | Nitric oxide synthase 2 and cyclooxygenase 2 interactions in inflammation |
| Q56908682 | Non-HLA genes and the susceptibility to insulin dependent diabetes: the role of the CTLA-4 gene |
| Q35557615 | Non-apoptotic functions of caspases in cellular proliferation and differentiation |
| Q34415756 | Nonlymphoid Fas ligand in peptide-induced peripheral lymphocyte deletion |
| Q37248354 | Novel molecular and cellular therapeutic targets in acute lymphoblastic leukemia and lymphoproliferative disease |
| Q34397101 | Of mice and men: the relevance of the mouse to the study of human SLE. |
| Q73590802 | Oligoclonal expansion of CD45RO+ T lymphocytes in Omenn syndrome |
| Q33541431 | On costimulatory signals and T cell tolerance: relevance for transplantation immunity. |
| Q34428954 | Onset of autoimmune lymphoproliferative syndrome (ALPS) in humans as a consequence of genetic defect accumulation |
| Q38823961 | Optimal Management of Autoimmune Lymphoproliferative Syndrome in Children |
| Q89977010 | Oral Microbes and Mucosal Dendritic Cells, "Spark and Flame" of Local and Distant Inflammatory Diseases |
| Q73348111 | Over-expression of the decoy receptor 3 (DcR3) gene in peripheral blood mononuclear cells (PBMC) derived from silicosis patients |
| Q37691426 | Overexpression of Mcl-1 exacerbates lymphocyte accumulation and autoimmune kidney disease in lpr mice. |
| Q42252275 | Overexpression of membrane-bound fas ligand (CD95L) exacerbates autoimmune disease and renal pathology in pristane-induced lupus. |
| Q37798037 | PKC-θ is a Drug Target for Prevention of T Cell-Mediated Autoimmunity and Allograft Rejection |
| Q64892906 | Paradoxical CD4 Lymphopenia in Autoimmune Lymphoproliferative Syndrome (ALPS). |
| Q33383468 | Pathobiology of secondary immune thrombocytopenia |
| Q35257857 | Pathogenesis of juvenile chronic arthritis: genetic and environmental factors |
| Q35754536 | Pathological findings in human autoimmune lymphoproliferative syndrome |
| Q38200384 | Pathophysiology and spectrum of diseases caused by defects in lymphocyte cytotoxicity. |
| Q36148396 | Paths to understanding the genetic basis of autoimmune disease |
| Q41514577 | Pathways leading to cell death in T cells |
| Q28204372 | Pleiotropic defects in lymphocyte activation caused by caspase-8 mutations lead to human immunodeficiency |
| Q29620319 | Points of control in inflammation |
| Q40666242 | Porcine Fas-ligand gene: genomic sequence analysis and comparison with human gene. |
| Q52571131 | Possible Association of Multicentric Castleman's Disease with Autoimmune Lymphoproliferative Syndrome. |
| Q31104620 | Precise mapping of the CD95 pre-ligand assembly domain |
| Q73315105 | Prediction of the three-dimensional structure of the human Fas receptor by comparative molecular modeling |
| Q39232124 | Primary/Congenital Immunodeficiency: 2015 SH/EAHP Workshop Report-Part 5. |
| Q41894662 | Pro- and anti-apoptotic CD95 signaling in T cells |
| Q33847243 | Probiotic sonicates selectively induce mucosal immune cells apoptosis through ceramide generation via neutral sphingomyelinase |
| Q79828647 | Prognostic significance of the Fas-receptor/Fas-ligand system in cervical squamous cell carcinoma |
| Q46163524 | Programmed cell death (apoptosis) in cord blood lymphocytes |
| Q39120700 | Programmed cell death and the immune system |
| Q37773421 | Programmed cell death of dendritic cells in immune regulation |
| Q45888106 | Programmed cell death: the influence of CD40, CD95 (Fas or Apo-I) and their ligands |
| Q36659578 | Proteasome regulation of activation-induced T cell death |
| Q38076413 | Protecting and rescuing the effectors: roles of differentiation and survival in the control of memory T cell development |
| Q37950926 | RIP1-mediated regulation of lymphocyte survival and death responses |
| Q40245571 | Rapid CD40-mediated rescue from CD95-induced apoptosis requires TNFR-associated factor-6 and PI3K. |
| Q41728141 | Recent advances. Immunology |
| Q41737516 | Receptors and ligands that mediate activation-induced death of T cells |
| Q36375186 | Recombinant galectin-1 and its genetic delivery suppress collagen-induced arthritis via T cell apoptosis |
| Q90041758 | Regulation of B-cell function by NF-kappaB c-Rel in health and disease |
| Q23910429 | Regulation of Fas (CD95)-induced apoptosis by nuclear factor-KB and tumor necrosis factor- alpha in macrophages |
| Q28592335 | Regulation of Fas ligand expression and cell death by apoptosis-linked gene 4 |
| Q37306636 | Regulation of Fas-mediated immune homeostasis by an activation-induced protein, Cyclon. |
| Q36368347 | Regulation of fas ligand expression during activation-induced cell death in T cells by p38 mitogen-activated protein kinase and c-Jun NH2-terminal kinase. |
| Q36562855 | Regulatory T cells in human autoimmune diseases |
| Q42436232 | Regulatory role of CD95 ligation on human B cells induced in vivo capable of spontaneous and high-rate Ig secretion |
| Q57384656 | Resistance of cultured peripheral T cells towards activation-induced cell death involves a lack of recruitment of FLICE (MACH/caspase 8) to the CD95 death-inducing signaling complex |
| Q40826064 | Resistance to CD95-mediated apoptosis through constitutive c-FLIP expression in a non-Hodgkin's lymphoma B cell line. |
| Q35125091 | Review: Environmental exposure to mercury and its toxicopathologic implications for public health |
| Q24632569 | Revised diagnostic criteria and classification for the autoimmune lymphoproliferative syndrome (ALPS): report from the 2009 NIH International Workshop |
| Q33376403 | Rituximab responsive immune thrombocytopenic purpura in an adult with underlying autoimmune lymphoproliferative syndrome due to a splice-site mutation (IVS7+2 T>C) affecting the Fas gene |
| Q41102922 | Role of Fas-mediated cell death in the regulation of immune responses |
| Q35084896 | Role of endogenous retroviruses in autoimmune diseases |
| Q35107838 | Role of inherited defects decreasing Fas function in autoimmunity. |
| Q37365961 | Roles of interferon-gamma and interleukin-4 in murine lupus |
| Q36322794 | SPOTS: signaling protein oligomeric transduction structures are early mediators of death receptor-induced apoptosis at the plasma membrane |
| Q41399533 | Searching for genes involved in the pathogenesis of primary immunodeficiency diseases: lessons from mouse knockouts |
| Q37377927 | Sequential decisions on FAS sequencing guided by biomarkers in patients with lymphoproliferation and autoimmune cytopenia |
| Q33588768 | Serum markers of apoptosis decrease with age and cancer stage |
| Q34563012 | Signaling to gene activation and cell death by tumor necrosis factor receptors and Fas. |
| Q74556952 | Significant role of Fas ligand-binding but defective Fas receptor (CD95) in lymph node hyperplasia composed of abnormal double-negative T cells |
| Q77312788 | Soluble Fas mRNA is dominantly expressed in cases with silicosis |
| Q34149957 | Somatic KRAS mutations associated with a human nonmalignant syndrome of autoimmunity and abnormal leukocyte homeostasis |
| Q41908763 | Somatic mutation of the CD95 gene in human B cells as a side-effect of the germinal center reaction |
| Q35092629 | Specific elimination of effector memory CD4+ T cells due to enhanced Fas signaling complex formation and association with lipid raft microdomains |
| Q36400965 | Spontaneous development of plasmacytoid tumors in mice with defective Fas-Fas ligand interactions |
| Q43014937 | Structural insight for the roles of fas death domain binding to FADD and oligomerization degree of the Fas-FADD complex in the death-inducing signaling complex formation: a computational study |
| Q41276439 | Suicide by order: some open questions about the cell-killing activities of the TNF ligand and receptor families |
| Q47611305 | Survival of autoreactive T lymphocytes by microRNA-mediated regulation of apoptosis through TRAIL and Fas in type 1 diabetes. |
| Q35183209 | Survival signals in leukemic large granular lymphocytes |
| Q77892082 | Susceptibility to lupus nephritis in the NZB/W model system |
| Q35148616 | Systemic lupus erythematosus and apoptosis: a question of balance |
| Q34082803 | Systemic lupus erythematosus, complement deficiency, and apoptosis |
| Q36399210 | T cell-specific ablation of Fas leads to Fas ligand-mediated lymphocyte depletion and inflammatory pulmonary fibrosis |
| Q36473831 | T cell-tumor cell: a fatal interaction? |
| Q34093608 | T-cell receptor complex is essential for Fas signal transduction. |
| Q34716347 | T-cell signalling and autoimmunity: molecular mechanisms of disease |
| Q39877053 | T-lymphocyte downregulation after acute viral infection is not dependent on CD95 (Fas) receptor-ligand interactions. |
| Q73411964 | TCR stimulation protects CD8+ T cells from CD95 mediated apoptosis |
| Q59783966 | TNF-related ligands and their receptors |
| Q33971049 | TNFRSF1A mutations and autoinflammatory syndromes |
| Q64900451 | TRAIL and FasL Functions in Cancer and Autoimmune Diseases: Towards an Increasing Complexity. |
| Q30988219 | TRAIL death receptor-4, decoy receptor-1 and decoy receptor-2 expression on CD8+ T cells correlate with the disease severity in patients with rheumatoid arthritis |
| Q64078760 | TRAIL-R1 and TRAIL-R2 Mediate TRAIL-Dependent Apoptosis in Activated Primary Human B Lymphocytes |
| Q37111489 | Targeted genomic analysis reveals widespread autoimmune disease association with regulatory variants in the TNF superfamily cytokine signalling network |
| Q71794021 | Targeted mutation in the Fas gene causes hyperplasia in peripheral lymphoid organs and liver |
| Q35577256 | The "fuzzy logic" of the death-inducing signaling complex in lymphocytes |
| Q57078448 | The Autoimmune Lymphoproliferative Syndrome with Defective FAS or FAS-Ligand Functions |
| Q35031256 | The Bcl-2 protein family: sensors and checkpoints for life-or-death decisions |
| Q33533982 | The CD95(APO-1/Fas)/CD95L system |
| Q34047933 | The Caenorhabditis elegans mucolipin-like gene cup-5 is essential for viability and regulates lysosomes in multiple cell types |
| Q54967366 | The Effect of a Competitive Futsal Match on T Lymphocyte Surface Receptor Signaling and Functions. |
| Q36367323 | The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand |
| Q41515265 | The Fas pathway in apoptosis. |
| Q24302236 | The Fas-FADD death domain complex structure reveals the basis of DISC assembly and disease mutations |
| Q24621785 | The Fas-associated death domain protein is required in apoptosis and TLR-induced proliferative responses in B cells |
| Q36114138 | The Fas/CD95 Receptor Regulates the Death of Autoreactive B Cells and the Selection of Antigen-Specific B Cells |
| Q34459289 | The Fas/Fas ligand pathway and Bcl-2 regulate T cell responses to model self and foreign antigens |
| Q44196945 | The anti-inflammatory sesquiterpene lactone parthenolide suppresses CD95-mediated activation-induced-cell-death in T-cells |
| Q37294307 | The apoptotic members CD95, BclxL, and Bcl-2 cooperate to promote cell migration by inducing Ca(2+) flux from the endoplasmic reticulum to mitochondria |
| Q34195490 | The autoimmune lymphoproliferative syndrome. A disorder of human lymphocyte apoptosis |
| Q28264600 | The autoimmune lymphoproliferative syndrome: an experiment of nature involving lymphocyte apoptosis |
| Q25256839 | The cancer stem cell: evidence for its origin as an injured autoreactive T cell |
| Q34283820 | The caspase 8 inhibitor c-FLIP(L) modulates T-cell receptor-induced proliferation but not activation-induced cell death of lymphocytes |
| Q77577103 | The clinical spectrum in a large kindred with autoimmune lymphoproliferative syndrome caused by a Fas mutation that impairs lymphocyte apoptosis |
| Q40707239 | The conformational alteration of the mutated extracellular domain of Fas in an adult T cell leukemia cell line |
| Q42067854 | The death domain of FADD is essential for embryogenesis, lymphocyte development, and proliferation |
| Q33996534 | The death domain superfamily in intracellular signaling of apoptosis and inflammation |
| Q35116679 | The death effector domain protein family: regulators of cellular homeostasis |
| Q37828761 | The emergence of ADAM10 as a regulator of lymphocyte development and autoimmunity |
| Q34573771 | The enemy within: keeping self-reactive T cells at bay in the periphery |
| Q39805021 | The expression of Fas Ligand by macrophages and its upregulation by human immunodeficiency virus infection. |
| Q35855040 | The genetics of familial lymphomas |
| Q37989934 | The immunogenetic architecture of autoimmune disease |
| Q34205697 | The many roles of FAS receptor signaling in the immune system |
| Q33836041 | The molecular basis for apoptotic defects in patients with CD95 (Fas/Apo-1) mutations |
| Q41692805 | The molecular basis of intractable diarrhoea of infancy |
| Q24685932 | The molecular pathology of primary immunodeficiencies |
| Q28139188 | The multifaceted role of Fas signaling in immune cell homeostasis and autoimmunity |
| Q34584971 | The origin of CD95-gene mutations in B-cell lymphoma |
| Q36401438 | The peripheral deletion of autoreactive CD8+ T cells induced by cross-presentation of self-antigens involves signaling through CD95 (Fas, Apo-1). |
| Q34009654 | The power and the promise of restimulation-induced cell death in human immune diseases |
| Q34071289 | The pre-ligand binding assembly domain: a potential target of inhibition of tumour necrosis factor receptor function |
| Q74012642 | The regulation of FasL expression--a distinquishing feature between monocytes and T lymphocytes/NK cells with possible implications for SLE |
| Q33636111 | The role of Fas and related death receptors in autoimmune and other disease states |
| Q73205341 | The role of Fas in autoimmune diabetes |
| Q33898921 | The role of fas ligand in vivo as a cause and regulator of pathogenesis |
| Q41659044 | The role of the bcl-2/ced-9 gene family in cancer and general implications of defects in cell death control for tumourigenesis and resistance to chemotherapy |
| Q71066518 | The roles of costimulation and Fas in T cell apoptosis and peripheral tolerance |
| Q33500825 | The spectrum of Evans' syndrome |
| Q64044425 | The technological transformation of patient-driven human immunology research |
| Q37852758 | The tumour necrosis factor/TNF receptor superfamily: therapeutic targets in autoimmune diseases |
| Q33955244 | Thyroid cell apoptosis. A new understanding of thyroid autoimmunity |
| Q41850711 | Trifluoperazine regulation of calmodulin binding to Fas: a computational study |
| Q40975748 | Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. |
| Q74497763 | Up-regulation of Fas ligand (FasL) mRNA expression in peripheral blood mononuclear cells (PBMC) after major surgery |
| Q35575327 | Update on primary immunodeficiency: defects of lymphocytes |
| Q33420245 | Updated Understanding of Autoimmune Lymphoproliferative Syndrome (ALPS). |
| Q24643047 | Use of rituximab for refractory cytopenias associated with autoimmune lymphoproliferative syndrome (ALPS) |
| Q34809111 | Variations of the UNC13D gene in patients with autoimmune lymphoproliferative syndrome |
| Q36880053 | Vitamin E and apoptosis |
| Q24309135 | Whole-exome-sequencing-based discovery of human FADD deficiency |
| Q41688188 | Why do defects in the Fas-Fas ligand system cause autoimmunity? |
| Q73047439 | [Thymus: old gland, new ideas] |
| Q36405075 | cFLIP regulation of lymphocyte activation and development |
Search more.